Hospira, Inc. Taxotere Ruling A Positive For Shareholders

Delaware District Court ruling on the Taxotere patents is seen as a meaningful positive for Hospira, Inc. HSP according to a J.P. Morgan research report. J.P.Morgan writes, "While we anticipate temporary restraining order/preliminary injunction requests from Sanofi, we believe this ruling could pave the way for Hospira's generic entry in November 2010. Along these lines, we are raising 2011-2013 estimates for the company to account for generic Taxotere ($1.25 bn LTM IMS branded sales) and reiterate our OW rating." Price Target for HSP is being raised from $62.00 to a $66.00 a share. HSP shares closed Monday at $57.10.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentJ.P.Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!